Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

SYRE holding history

Spyre Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

SYRE overviewAll 13F holders of SYREFull Q2 2026 holdings

Shares (Q2 2026)
843,071
Value
$74.8M
% of portfolio
<0.1%
Quarters held
20
Since Q1 2021
Holdings of SYRE by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026843,071$74.8M<0.1%+171,836+25.6%AddedHolders
Q1 2026671,235$33.9M<0.1%−9,331−1.4%ReducedHolders
Q4 2025680,566$22.3M<0.1%+294,977+76.5%AddedHolders
Q3 2025385,589$6.46M<0.1%−77,274−16.7%ReducedHolders
Q2 2025462,863$6.93M<0.1%−89,380−16.2%ReducedHolders
Q1 2025552,243$8.91M<0.1%+160,046+40.8%AddedHolders
Q4 2024392,197$9.13M<0.1%+334,359+578.1%AddedHolders
Q3 202457,838$1.70M<0.1%+13,334+30.0%AddedHolders
Q2 202444,504$1.05M<0.1%+41,903+1,611.0%AddedHolders
Q1 20242,601$98.7K<0.1%−1,125−30.2%ReducedHolders
Q4 20233,726$80.2K<0.1%+3,726NewHolders
Q3 20230$00.0%−324−100.0%Sold outConverted for a 1-for-25 splitHolders
Q2 20238,091$3.65K<0.1%+8,084+115,485.7%AddedHolders
Q1 20237$2<0.1%−1−12.5%ReducedHolders
Q4 20228$4<0.1%+8NewHolders
Q3 20220$00.0%−76,806−100.0%Sold outHolders
Q2 202276,806$39.0K<0.1%+11,530+17.7%AddedHolders
Q1 202265,276$150.0K<0.1%−71,360−52.2%ReducedHolders
Q4 2021136,636$649.0K<0.1%+82,416+152.0%AddedHolders
Q3 202154,220$431.0K<0.1%+2,143+4.1%AddedHolders
Q2 202152,077$362.0K<0.1%+2,104+4.2%AddedHolders
Q1 202149,973$396.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.